sellWeak10b5-1 plan
Carl Dambkowski sold $103k of APGE
Chief Medical Officer at Apogee Therapeutics, Inc.. 2,725 shares at an average of $37.87, traded Sep 3, 2025, filed Sep 5, 2025.
Warning score
5Value
$103k
2,725 shares
Holdings after
233,548
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +10Trade size$103k at market
- 0Share of holdings soldSold 1.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-087939, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,535 | $37.82 | $96k | 233,738 | Sep 5, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -190 | $38.55 | $7,325 | 233,548 | Sep 5, 2025 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $120k 1,500 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $3.0M 40,000 shares | -3% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $113k 1,500 shares | -1% | |
| 32Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $818k 10,900 shares | -4% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $105k 1,500 shares | -1% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $130k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 24Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $60k 1,000 shares | -0% | |
| 14Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $594k 10,785 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.